Sfoglia per AUTORE
LANDI L
Collezione AOU Novara

  

Items : 6

Combi-TED: a new trial testing Tedopi(®) with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. in Future oncology (London, England) / Future Oncol. 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22.

2022
AOU Novara

Landi L; Delmonte A; Bonetti A; Pasello G; Metro G; Mazzoni F; Borra G; Giannarelli D; Andrikou K; Mangiola D; Gori S; D'Andrea MR; Minuti G; Resuli B; Laudisi A; Vidiri A; Conti L; Cappuzzo F;

Post-progression outcomes of NSCLC patients with PD-L1 expression ? 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.

2021
AOU San Luigi di Orbassano
AO Ordine Mauriziano
AOU Novara

Russo A; Adamo V; Metro G; De Filippis M; Simona C; Natalizio S; Migliorino MR; Ricciardi S; Landi L; Minuti G; Buti S; Nigro O; Cantini L; Russano M; Citarella F; Bracarda S; Filetti M; Zoratto F; Mansueto G; De Tursi M; Gori S; Rocco D; Chiari R; Rastelli F; Gelibter A; Targato G; Signorelli D; De Toma A; Mazzoni F; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cannita K; Porzio G; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Russo A; Adamo V; Metro G; Olmetto E; Tabbò F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Tuzi A; Bisonni R; Follador A; Siringo M; Gelibter A; Signorelli D; De Toma A; Garassino MC; Mazzoni F; Russano M; Citarella F; Filetti M; Zoratto F; Mansueto G; et alii...

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. in Journal for immunotherapy of cancer / J Immunother Cancer. 2021 Apr;9(4):e002421. doi: 10.1136/jitc-2021-002421.

2021
AOU San Luigi di Orbassano
ASL Città di Torino
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Russo A; Adamo V; Metro G; Bironzo P; Passiglia F; Migliorino MR; Ricciardi S; Landi L; Minuti G; Bordi P; Tuzi A; Cantini L; Russano M; Citarella F; Santini D; Filetti M; Zoratto F; Mansueto G; Di Marino P; Grassadonia A; Michele T; Inno A; Della Gravara L; Rocco D; Chiari R; Rastelli F; Macerelli M; Marchetti P; Siringo M; et alii...

Listening understanding and acting (lung): focus on communicational issue in thoracic oncology. in Translational cancer research / Transl Cancer Res. 2019 Jan;8(Suppl 1):S16-S22. doi: 10.21037/tcr.2018.12.32.

2019
AOU San Luigi di Orbassano
AOU Novara

Romano G; Roca E; Morabito A; Montrone M; Minotti V; Migliorino MR; Melotti B; Mazzanti P; Martelli O; Malorgio F; Mancuso G; Landi L; Irtelli L; Gregorc V; Gilli M; Franchina T; Del Conte A; D'Argento E; Cusmai A; Danesi R; Costanzo R; Cortinovis D; Carta A; Bulotta A; Buffoni L; Borra G; Bettini A; Bianco R; Barbieri V; et alii...

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2019 Dec 15;25(24):7312-7319. doi: 10.1158/1078-0432.CCR-19-0994. Epub 2019 Aug 15.

2019
AOU Novara

Landi L; Chiari R; Tiseo M; D'Incà F; Dazzi C; Chella A; Delmonte A; Bonanno L; Giannarelli D; Cortinovis DL; de Marinis F; Borra G; Morabito A; Gridelli C; Galetta D; Barbieri F; Grossi F; Capelletto E; Minuti G; Mazzoni F; Verusio C; Bria E; Alì G; Bruno R; Proietti A; Fontanini G; Crinò L; Cappuzzo F;